TomerMarkMD

PubMed

• CD46-ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts.
  Michael J VanWyngarden, Zachary J Walker, Yang Su, Olivia Perez de Acha, Brett M Stevens, Peter A Forsberg, Tomer M Mark, William Matsui, Bin Liu, Daniel W Sherbenou> ;Cancers. 2023 Nov 9
• 3 citations
  CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
  Olivia Perez de Acha, Lauren Reiman, David S Jayabalan, Zachary J Walker, Grace Bosma, Alana L Keller, Sarah E Parzych, Diana Abbott, Beau M Idler, Drew Ribadeneyra, R...> ;Blood Advances. 2023 Nov 14
• Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors.
  Adam F Binder, Christopher J Walker, Tomer M Mark, Muhamed Baljevic> ;Frontiers in Immunology. 2023 Jan 1
• 25 citations
  Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
  Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria-Victoria Mateos, Tomer M ...> ;Journal of Clinical Oncology. 2023 Mar 10
• 1 citations
  Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.
  Stephanie Lakritz, Peter A Forsberg, Daniel W Sherbenou, Tomer M Mark> ;Clinical Case Reports. 2022 Sep 1
• 9 citations
  Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies.
  Margaret E Stalker, Tomer M Mark> ;Current Oncology. 2022 Jun 23
• 2 citations
  Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
  Alana L Keller, Daniel W Sherbenou, Peter A Forsberg, Tomer M Mark> ;Frontiers in Oncology. 2022 Jan 1
• 5 citations
  Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma.
  Tomer M Mark, Angelica Falkenstein, Jonathan Kish> ;Future Oncology. 2021 Nov 17
• 1 citations
  Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple mye...
  Peter A. Forsberg, Adriana C Rossi, Angelique Boyer, Roger N. Pearse, Karen Pekle, David Jayabalan, Stephanie Lakritz, Kari Flicker, Drew Ribadeneyra, Brielle Liotta, ...> ;American Journal of Hematology. 2021 Sep 4
• Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
  Daniel W. Sherbenou, Peter A. Forsberg, Tomer M Mark, Margaret Stalker> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Mar 19
• 1 citations
  Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma
  Nina Orfali, Yuliya S. Jhanwar, Calvin Koo, Michelle Pasciolla, Maria Baldo, Edwidge Cuvilly, Richard R. Furman, Usama Gergis, June Greenberg, Danielle Guarneri, Jingm...> ;Leukemia & Lymphoma. 2021 Feb 13
• 9 citations
  Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib an...
  Vania Hungria, Meral Beksac, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Ivan Spicka, Markus Munder, Maria-Victoria Mateos, Tomer M Mark, Ming Qi, Xiang Qin, John Faste...> ;British Journal of Haematology. 2021 Feb 8
• 5 citations
  Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
  Zachary J. Walker, Beau M Idler, Lorraine N Davis, Brett M. Stevens, Michael J VanWyngarden, Denis Ohlstrom, Shelby C. Bearrows, Andrew Hammes, Clayton A. Smith, Craig...> ;Clinical Cancer Research. 2021 Feb 1
• 4 citations
  Daratumumab-induced Choroidal Effusion: A Case Report and Review of the Literature.
  Anne Strong, Michael J. Huvard, Jeffrey L. Olson, Tomer M Mark, Cara E Capitena Young> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Sep 19
• 31 citations
  Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
  Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M Mark, Ivan Spicka, Tamás Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hung...> ;Journal of Hematology & Oncology. 2020 Aug 20
• 35 citations
  Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.
  Prashant Sharma, Enkhtsetseg Purev, Bradley M. Haverkos, Daniel A. Pollyea, Evan Cherry, Manali Kamdar, Tomer M Mark, Peter A. Forsberg, Daniel W. Sherbenou, Andrew Ha...> ;Blood Advances. 2020 May 26
• 12 citations
  Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.
  Zachary J. Walker, Michael J VanWyngarden, Brett M. Stevens, Diana Abbott, Andrew Hammes, Christophe J. Langouët-Astrié, Clayton A. Smith, Brent E. Palmer, Peter A. Fo...> ;Blood Advances. 2020 Apr 28
• 17 citations
  High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
  Alexandra Gomez-Arteaga, Tomer M Mark, Danielle Guarneri, Paul J. Christos, Usama Gergis, June Greenberg, Jingmei Hsu, Sebastian Mayer, Ruben Niesvizky, Roger N. Pears...> ;Bone Marrow Transplantation. 2019 Jun 12
• 4 citations
  Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
  Peter A. Forsberg, Adriana C Rossi, Angelique Boyer, Linda Tegnestam, Roger N. Pearse, Arthur Perry, Karen Pekle, David Jayabalan, Scott Ely, Leora Boussi, Daniel W. S...> ;American Journal of Hematology. 2019 May 1
• 17 citations
  Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma
  Sathish Kumar Gopalakrishnan, Anita D'Souza, Emma C. Scott, Raphael Fraser, Omar Davila, Nina Shah, Robert Peter Gale, Rammurti T. Kamble, Miguel Angel Diaz, Hillard M...> ;Biology of Blood and Marrow Transplantation. 2019 Apr 1
• 10 citations
  Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
  Tomer M Mark, Peter A. Forsberg, Adriana C Rossi, Roger N. Pearse, Karen Pekle, Arthur Perry, Angelique Boyer, Linda Tegnestam, David Jayabalan, Morton Coleman, Ruben ...> ;Blood Advances. 2019 Feb 26
• 2 citations
  Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma.
  Peter A. Forsberg, Andrew Hammes, Diana Abbott, Daniel W. Sherbenou, Adriana C Rossi, David Jayabalan, Ruben Niesvizky, Tomer M Mark, Scott Ely> ;Leukemia &amp; Lymphoma. 2019 Jan 11
• 202 citations
  Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
  Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M Mark, Ivan Spicka, Tamás Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hung...> ;Haematologica. 2018 Dec 1
• 11 citations
  Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most ...
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Biology of Blood and Marrow Transplantation. 2018 Dec 1
• 25 citations
  Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
  Ajai Chari, Sagar Lonial, Tomer M Mark, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z. Usmani, Anil Londhe, Delores Etheredge, Sarah Fleming, Baolian Liu, Jon Ukro...> ;Cancer. 2018 Nov 15
• Join now to see all

Journal Articles

• Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Sur...  
  Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, ..., Biol Blood Marrow Transplant, 1/24/2017
• Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices  
  Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K, Biol Blood Marrow Transplant, 1/20/2017
• Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Naïve Patients  
  Ely S, Forsberg P, Ousansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D, Di Liberto M, Chen-Kiang S, Niesvizky R, Mark TM, Clin Lymphoma Myeloma Leuk, 1/20/2017
• Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  
  Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C..., Biol Blood Marrow Transplant, 1/1/2017
• Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma  
  Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt ..., Biol Blood Marrow Transplant, 1/1/2017
• A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma  
  Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou..., Biol Blood Marrow Transplant, 1/1/2017
• Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future  
  Sherbenou DW, Mark TM, Forsberg P, Clin Lymphoma Myeloma Leuk, 1/1/2017
• Practical Approaches to Management of Dual Refractory Multiple Myeloma  
  Lee HC, Mark T, Shah J, Curr Hematol Malig Rep, 1/22/2016
• Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis  
  Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazaru..., Biol Blood Marrow Transplant, 1/1/2016
• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma  
  Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi..., N Engl J Med, 1/1/2016
• Clonal Plasma Cells Keep Strange Company  
  Mark TM, Pekle K, Leuk Lymphoma, 1/1/2016
• Cord blood chimerism and relapse after haplo-cord transplantation  
  van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T, Leuk Lymphoma, 1/1/2016
• Haplo-cord transplant: HLA-matching determines graft dominance  
  van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T, Leuk Lymphoma, 1/1/2016
• It's Time to Take Clarithromycin Seriously in Multiple Myeloma  
  Mark TM, Coleman M, Acta Haematol, 1/1/2016
• Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation  
  Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gi..., Bone Marrow Transplant, 1/24/2015
• Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem ...  
  Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE, Walsh TJ, Gergis U, Biol Blood Marrow Transplant, 1/3/2015
• Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study  
  D’Souza A, Dispenzieri A, Wirk B, Zhang M-J, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter G, Robert, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Fr..., Journal of Clinical Oncology, 1/1/2015
• Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature  
  Novikov A, Holzer H, DeSimone RA, Abu-Zeinah G, Pisapia DJ, Mark TM, Pastore RD, Case Reports in Oncological Medicine, 1/1/2015
• T-BiRD (thalidomide, clarithromycin, lenalidomide and dexamethasone) therapy in newly diagnosed, symptomatic multiple myeloma  
  Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R, Leuk Lymphoma, 1/28/2014
• A strategy to reduce donor-specific HLA Abs before allogeneic transplantation  
  Gergis U, Mayer S, Gordon B, Mark T, Pearse R, Shore T, Van Besien K, Bone Marrow Transplant, 1/17/2014
• Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma  
  Mark TM, Coleman M, Niesvizky R, Leuk Res, 1/13/2014
• A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma  
  Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T, Biol Blood Marrow Transplant, 1/20/2013
• Pomalidomide: New immunomodulatory agent with potent antiproliferative effects  
  Richardson PG, Mark T, and Lacy MQ, Crit Rev Oncol Hematol, 1/17/2013
• Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization  
  Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K, Xiang Z, Ely S, Skerret D, Chen-Kiang S, C..., Clin Cancer Res, 1/1/2013
• A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute l...  
  Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E, Biol Blood Marrow Transplant, 1/1/2013
• Join now to see all

Books/Book Chapters

• Wintrobe’s Atlas of Clinical Hematology 
  Chapter: Plasma Cell Disorders. 
  Mark T, Schechter GPLippincott Williams & WilkinsEdition 2nd,2017
• Knowles’ Neoplastic Hematopathology 
  Chapter: B-cell immunoproliferative disorders, including multiple myeloma and primary amyloidosis. 
  Ely S, Niesvizky R, Mark TLippincott Williams & WilkinsEdition 3rd,2013
• Love, Olivia. 
  Chin O, Mark TWestBow Press2012
• Myeloma Therapy: Pursuing the Plasma Cell. 
  Chapter: Pathophysiology of Bone Disease in Multiple Myeloma. 
  Page 435 - 454Mark T, Pearse RNEditors: S. Lonial.Humana Press, Totowa, NJ2008
• Join now to see all

Abstracts/Posters

• Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples
  Tomer M Mark, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy and Safety of Daratumumab, Bortezomib and Dexamethasone (Dvd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Upda...
  Weisel K, Lentzsch S, Mateos MV, Hungria V, Munder M, Nooka A, Mark T, Quach H, Scott EC, Lee JJ, Sonneveld P, Casneuf T, Chiu C, Qin X, Amin H, Thiyagarajah P, Schect..., Haematologica; European Hematology Association Meeting, 1/1/2017
• Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma.
  Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, Etheredge D, Parros H, Fleming S, Liu BL, Freeman S, Ukropec J, Lin T, Lonial S, American Society of Hematology, 1/1/2016
• Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Mye...
  Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, Etheredge D, Parros H, Fleming S, Liu BL, Freeman S, Ukropec J, Lin T, Nooka AK, American Society of Hematology, 1/1/2016
• Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM).
  Forsberg PA, Rossi AC, Pearse RN, Perry A, Pekle K, Jayabalan D, Ely S, Coleman M, Allan JN, Niesvizky R, Mark T, American Society of Hematology, 1/1/2016
• Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study.
  Kumar S, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O&#39;Donnell EK, Vij..., American Society of Hematology, 1/1/2016
• Patients (pts) with Renal Insufficiency (RI) and Multiple Myeloma (MM) Have Similar Outcomes after Autologous Hematopoietic Cell Transplantation (AHCT) As Those without.
  Mahindra A, Hari P, Fraser R, Fei MW, Mark T, Nieto Y, D&#39;Souza A., American Society of Hematology, 1/1/2016
• Cost Effectiveness of Cell Proliferation vs. Cytogenetics for Risk Stratification in Multiple Myeloma.
  Ely, S, Tacha S, Forsberg P, Ouansafi I, Niesvizky R, and Mark T, Laboratory Investigation; United States and Canadian Academy of Pathology Meeting, 1/1/2016
• Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple...
  Weisel K, Palumbo A, Chanan-Khan A, Nooka AK, Spicka I, Masszi T, Beksac M, Hungria V, Munder M, Mateos MV, Mark TM, Spencer A, Qi M, Schecter J, Amin H, Qin X, Deraed..., Ann Oncol; European Society of Medical Oncology Meeting, 1/1/2016
• Extracorporeal Apheresis Via AV Fistula in Multiple Myeloma Patients with End Stage Renal Disease.
  Bourke J, Mark TM, Silberzweig J, Enriquez U, van Besien K, Herbert B, et al, Biol Blood Marrow Tr; American Society for Blood and Marrow Transplantation Tandem Meeting, 1/1/2016
• Outcomes after Allogeneic Transplant for Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia (Lpl/Wm): A Center for International Blood and Marrow Transplant Rese...
  Cornell, RF, Bachanova V, D&#39;Souza A, Ahn KW, Huang JX, Krishnan A, Gasparetto C, Nieto Y, Mark TM, and Hari PN, Biol Blood Marrow Tr; American Society for Blood and Marrow Transplantation Tandem Meeting, 1/1/2016
• Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma.
  Diamond, B, Rossi AC, Pearse RN, Jayabalan D, Perry A, Pekle K, Mark T, and Niesvizky R, Blood; American Society of Hematology, 1/1/2016
• Phase 3 Randomised Controlled Study of Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple M...
  Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark T, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi ..., Haematologica; European Hematology Association Meeting, 1/1/2016
• Plasma cell proliferation by SynKii multiplex immunohistochemistry (mIHC) for clinical use in multiple myeloma (MM).
  Ely S, Forsberg P, Niesvizky R, Mark TM, J Clin Oncol; American Society of Clinical Oncology Meeting, 1/1/2016
• Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM).
  Cornell RF, Costa LJ, Kassim AA, Inns-Shelton R, Krishnan A, Mark T, Nieto Y, Gasparetto CJ, D&#39;Souza A, Hari P, Zhang MJ, Huang J, American Society of Hematology Meeting, 1/1/2015
• Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma.
  Forsberg P, Mark TM, Yadlapati S, Rossi AC, Pearse RN, Pekle K, Perry A, Coleman M, Jayabalan D, Niesvizky R, Ely S, American Society of Hematology Meeting, 1/1/2015
• Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation.
  Huang X, Jayabalan D, Liberto M, Chen Z, Schinzel AC, Ely S, Rossi AC, Pearse RN, Aneja E, Coleman M, Lane JM, Hahn WC, Mark TM, Niesvizky R, Chen-Kiang S, American Society of Hematology Meeting, 1/1/2015
• CLAPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and...
  Mark TM, Boyer A, Yadlapati S, Rossi AC, Pearse RN, Pekle K, Perry A, Pogonowski K, Aneja E, Tegnestam L, Jayabalan D, Ely S, Coleman M, Huang X, Liberto M, Chen-Kian..., American Society of Hematology Meeting, 1/1/2015
• High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma.
  Mark TM, Yadlapati S, Neglyad L, Bourke J, Jayabalan D, Rossi AC, Pearse RN, Perry A, Pekle K, Pogonowski K, Tegnestam L, Huang X, Liberto M, Ely S, Coleman M, Chen-K..., American Society of Hematology Meeting, 1/1/2015
• Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF.
  Allan JN, Jayabalan D, Niesvizky R, Mark TM, Pearse RN, MD, Rossi AC, Tegnestam L, Hassane DC, Guzman M, American Society of Hematology Meeting, 1/1/2014
• Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation.
  Costa LJ, Uy GL, Hari PN, Zhang MJ, Huang J, Krishnan A, Mark TM, D&#39;Souza A, American Society of Hematology Meeting, 1/1/2014
• Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Regi...
  D&#39;Souza A, Wirk B, Zhang MJ, Huang J, Krishnan A, Mark TM, Gasparetto CJ, Hari PN, American Society of Hematology Meeting, 1/1/2014
• The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma.
  Mark TM, Forsberg P, Ouansafi I, Rossi AC, Pearse TN, MD, Pekle K, Perry A, Coleman M, Jayabalan D, Niesvizky R, Ely SA, American Society of Hematology Meeting, 1/1/2014
• Car-Bird [Carfilzomib, Clarithromycin(Biaxin), Lenalidomide/ (Revlimid), Dexamethasone) for Newly-Diagnosed Multiple Myeloma.
  Mark TM, MD, Schickner A, Allan JN, Rossi AC, Pearse RN, Tegnestam L, Pekle K, Perry A, Pognowski K, Jayabalan J, Coleman M, Niesvizky R, American Society of Hematology Meeting, 1/1/2014
• A Comparison of Outcomes in the First-Line Treatment of Multiple Myeloma Presenting with Single Versus Multiple Monoclonal Paraproteins.
  Mark TM, Meadows JP, Koirala A, Jayabalan D, Niesvizky R, American Society of Hematology Meeting, 1/1/2014
• Join now to see all

Lectures

• Best of Myeloma at ASH 2016. 
  University of Colorado - 1/27/2017
• In the relapsed patient, what would be the ideal treatment? 
  New York, NY - 1/26/2017
• New Drugs in Multiple Myeloma 
  University of Colorado, Anschutz Medical Campus - 1/9/2017
• Amyloidosis 
  1/8/2017
• Plasma Cell Disorders, but Mostly Myeloma. 
  University of Colorado, Anschutz Medical Campus - 1/3/2017
• Treatment of Multiple Myeloma 
  University of Colorado, Anschutz Medical Campus - 1/3/2017
• Myeloma in 2016: What you need to know. 
  Oregon Health and Science University; Dartmouth-Hitchcock Hospital / Norris Cotton Cancer Center - 1/15/2016
• Monoclonal antibodies: A new wave for the future 
  New York, NY - 1/13/2016
• Plasma Cell Neoplasms 
  Weill Cornell Medical College - 1/1/2016
• Debate: Is transplant a necessity or a choice: Focus on the necessity for CR and MRD 
  New York, NY - 1/22/2015
• Multiple Myeloma in 2015: What you need to know 
  Wyckoff Heights Medical Center, Brooklyn, NY - 1/12/2015
• Induction therapies in transplant eligible patients 
  New York, NY - 1/23/2014
• Debate: Two vs Three Drugs in Multiple Myeloma 
  New York, NY - 1/26/2013
• Debate: What is the best induction therapy in transplant-eligible patients? 
  New York, NY - 1/24/2013
• Multiple Myeloma in 2012: What you need to know 
  University of Connecticut Health Science Center, West Hartford, CT, 2012; Fox Chase Cancer Center, P - 1/12/2013
• Session IV: Myeloma treatment presentation: Update on novel combinations for relapsed/refractory disease: Coming soon 
  New York, NY - 1/25/2012
• ClaPD (Clarithromycin/[Biaxin], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma, An Update 
  Atlanta, GA - 1/9/2012
• New treatments and how best to use them in lymphoma and myeloma Presentation: Pomalidomide 
  New York, NY - 1/21/2011
• ClaPD (Clarithromycin/[Biaxin], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma 
  Atlanta, GA - 1/12/2011
• Extended follow-up results of BiRD therapy: prolonged responses achieved. 
  Washington, DC - 1/26/2009
• Case presentation of multiple myeloma with audience participation 
  New York, NY - 1/16/2008
• Join now to see all